Published in Hepatitis Weekly, September 20th, 2004
Based on earlier studies showing the capability of SCV-07 to stimulate the immune system to fight disease, Verta will conduct this pilot HCV clinical trial to explore the potential anti-viral capabilities of SCV-07. SciClone has acquired the worldwide rights, outside of Russia, to SCV-07 from Verta and is conducting pre-clinical studies with the intention of filing an investigational new drug (IND) application in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.